discontinuation of glucagon-like peptide-1 receptor agonists Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists - New studies on GLP-1 discontinuation Understanding the Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

Is there sustained weight loss afterdiscontinuation ofGLP-1 agonist for obesity treatment The increasing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for managing type 2 diabetes and obesity has brought significant advancements in metabolic health. However, questions surrounding the discontinuation of GLP-1 receptor agonists are becoming increasingly prevalent.Thediscontinuationrate was 47.7% and 70.1% at 12 and 24 months, respectively, with differences at 24 months for age and dosing frequency (p<0.001 for both). Real-world observations and clinical studies highlight a concerning trend: a substantial proportion of patients discontinue these therapies, often within the first year of treatment. This article delves into the multifaceted implications of GLP-1 RA discontinuation, exploring the reasons behind it, the consequences for patients, and the ongoing research to address these challengesA new study reveals thatmost patients discontinue GLP-1 receptor agonists within a year, with significantly higher dropout rates among those using them for ....

High Discontinuation Rates and Contributing Factors

Evidence from numerous studies indicates that discontinuation rates for GLP-1 RAs are significant. Some reports suggest that as many as 50% to 75% of patients stop treatment within a year. For individuals with type 2 diabetes initiating GLP-1 RAs, one study found that the majority (70.1%) discontinued therapy by 24 months. Notably, discontinuation of GLP-1 receptor agonists appears to be higher in individuals with overweight and obesity without type 2 diabetesTriple–Hormone-Receptor Agonist Retatrutide for Obesity. Specificity in discontinuation timelines is also observed, with some data showing 26.2% at three months, 30.8% at six months, and 36.5% at 12 months.Discontinuation of glucagon-like peptide-1 receptor agonists

Several factors contribute to this high rate of discontinuation. These can range from the cost and accessibility of the medications to the presence of side effects, and the perceived lack of sustained benefits if not managed holistically. The definition of discontinuation can also vary, with one study noting that discontinuation is the first date a patient is 60 days or more without any GLP-1 RA medication on hand作者：GJ Grosicki·2025·被引用次数：5—Glucagon-like peptide-1 receptor agonists discontinuationis higher in individuals with overweight and obesitywithout type 2 diabetes..

Consequences of Discontinuation: Weight Regain and Metabolic Rebound

The most widely documented consequence of GLP-1 RA discontinuation is a significant weight regain after cessation of medication. Studies consistently show that individuals are likely to regain weight after discontinuing GLP1 RA therapy. This phenomenon is sometimes referred to as a "metabolic rebound." Research indicates that discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventionsGlucagon-like peptide-1 receptor agonists for obesity. The trajectory of this weight regain is predictable, often following a decelerating pattern that may plateau below pre-treatment levels, though the extent of this plateau can vary.

Beyond weight, the cessation of GLP-1 RAs can lead to a rebound in other metabolic parameters as well. In patients with type 2 diabetes, discontinuation of GLP-1 RAs was associated with significant rebound in body weight, systolic blood pressure, and glycemic controlDiscontinuation and Reinitiation of GLP-1 Receptor Agonists. This underscores the importance of sustained treatment for optimal long-term health outcomes. The loss of other benefits associated with these medications, such as cardiovascular and kidney protection, is also a significant concern following discontinuation.

The Role of GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic the action of the naturally occurring hormone glucagon-like peptide-1.作者：SS Khan·2025·被引用次数：34—This Viewpoint discusses the health benefits ofglucagon-like peptide-1 receptor agonists(GLP-1 RAs); summarizes the clinical, policy, and equity implications ... This hormone plays a crucial role in regulating blood glucose levels and appetite.Metabolic rebound after GLP-1 receptor agonist ... By activating the glucagon-like peptide-1 receptor, these agonists stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, all of which contribute to lower blood sugar and weight loss. Examples of these medications include semaglutide, liraglutide, and tirzepatide (which also acts on glucagon receptors)Real-world weight change, adherence, and discontinuation ....

Addressing the Challenges of Discontinuation

The high rates and significant consequences of GLP-1 RA discontinuation necessitate a proactive approach. Researchers are exploring various strategies to improve adherence and manage discontinuation.Discontinuation of Glucagon-Like Peptide-1 Receptor ... This includes investigating the long-term efficacy and safety of these drugs, developing newer GLP-1 receptor agonists and obesity diabetes treatments, and understanding the optimal duration of treatment. Furthermore, a focus on comprehensive patient education and support, alongside addressing the economic and policy implications, is crucial. The WHO issues global guideline on the use of GLP-1 receptor agonists, aiming to provide a framework for their appropriate and sustained use.

The ongoing research into real-world weight change, adherence, and discontinuation of these therapies is vitalStopping GLP-1 Weight Loss Drugs Leads to Fast .... Understanding the nuances of patient adherence, which can be influenced by factors like dosing frequency, is key to developing more effective treatment strategies. The persistence of weight gain after withdrawal or discontinuation remains a primary concern, driving the need for strategies that support sustained lifestyle changes alongside pharmacological interventionsMany Patients Quit Taking GLP-1 Drugs: Understanding ....

In conclusion, while glucagon-like peptide-1 receptor agonists have revolutionized the management of type 2 diabetes and obesity, the issue of discontinuation presents a significant challengeGlucagon-like peptide-1 receptor agonists for obesity. Addressing the underlying reasons for stopping treatment and mitigating the consequences, particularly weight regain and metabolic rebound, requires a collaborative effort involving healthcare providers, researchers, policymakers, and patients. The goal is to ensure that the profound health benefits offered by these agonists can be sustained for the long term.